Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
Date:8/5/2009

====== ====== ====== ====== Shares used to compute basic and diluted net loss per share 33,083,447 27,891,870 31,816,553 27,880,772 ========== ========== ========== ========== Optimer Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets June 30, December 31, 2009 2008 ---- ---- (unaudited) ASSETS Current assets: Cash and cash equivalents $26,217,128 $16,778,880 Short-term investments 24,935,778 22,547,515 Prepaid expenses and other current assets 810,556 744,670 ------- ------- Total current assets 51,963,462 40,071,065 Property and equipment, net 623,892 694,183 Long-term investments 882,000 1,032,000 Other assets 498,171 498,250 ------- ------- Total assets $53,967,525 $42,295,498 =========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $4,091,178 $3,767,831 Accrued expenses 4,099,069 4,045,660 --------- --------- Total current liabilities 8,190,247 7,813,491 Deferred r
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
2. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
4. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
6. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
8. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
9. Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level
10. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
11. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...RNewswire/ -- Dr. Mate Hidvegi, inventor of Avemar... release issued on November 17 by Biropharma Kft, ...e and self-serving statements about its U.S. compe...ted from his office in Budapest, Hungary: ,, "...not apply to AveULTRA, www.aveultra.com , is mi...
(Date:11/19/2009)...ovember 19 MONITORING FORCE GmbH,a...09 Flibanserin in the,indication treatment-relevan...se for orphan drug status designation with the Eur...skinesia is a complication of the mainstay,treatme... some of those,affected, since it may be disabling...
(Date:11/19/2009)...ovember 19 AFFiRiS AG will focus i...idate at an unexpectedly early,stage of developmen...into,Phase II clinical trial early in 2010. This d...pletion of two Phase I trials with the candidates,... on the first interim,analysis of the secondary en...
(Date:11/18/2009)...lfast are developing new sensors to detect chemica...fight against the threat of terrorist attacks. , ...an individual or crime scene to gather a sample wh... can detect the presence of chemicals within secon... made in response to terrorist threats. , The s...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3New technology detects chemical weapons in seconds 2
...ical Recoveries, FREDERICK, Md., March 13 BioEle...launch of its Breast Recovery Kit,for the relief o... by Dr. Barry Eppley, MD, DMD, the 1 Day Breast Re...n to their active lives the day,after surgery. Usi...ma and,discomfort without drugs, ice, or topical o...
...,privately-held biopharmaceutical company, announc...clinical trials sponsored by its wholly owned,subs...CollaRx(R),BUPIVACAINE SURGICAL IMPLANT for the ma...ing., Innocoll,s BUPIVACAINE SURGICAL IMPLANT is ...purified fibrillar collagen impregnated with the,l...
...ntists worldwide gain new insight i...seeks funding support for human brain, spinal cord...projects, SEATTLE, March 13 The Allen Institute ...taking three major projects designed to,accelerate...sts worldwide,gain new insight into numerous disea...
Other Biology Technology:BioElectronics Launches '1 Day Breast Augmentation Recovery Kit' 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 2Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 3Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 4Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord 5
(Date:11/20/2009)...y disease (COPD), a respiratory disease commonly k...urth leading cause of death worldwide. 600 millio... yet to find any real treatment or cure, Grace Par...ty of Western Ontario in London, Canada, is using ...o the disease. , Parraga is a scientist in t...
(Date:11/19/2009)...s ago, at the end of the last ice age, North Ameri...uch iconic creatures as mammoths, mastodons, camel...their precipitous slide to extinction. , And whe... diversity of large animals equaled or surpassed A..., an entirely novel ecosystem emerged as broadleav...
(Date:11/19/2009)... = more than 2: The offspring of two inbred strain...aracterizing the gene-level variability that leads...vigor, could boost our ability to custom-tailor cr...ent for human consumption or high glucose content ...leased DNA sequence of the common corn strain B73,...
Breaking Biology News(10 mins):Gaining a better picture of lung disease 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2Womens Health An Intimate Discussion 51623 1Womens Health An Intimate Discussion 51623 2Johns Hopkins Medical Institutions Deploys Perceptrak 28R 29 by Cernium 51620 1Johns Hopkins Medical Institutions Deploys Perceptrak 28R 29 by Cernium 51620 2Studies Presented at International Conference on Alzheimers Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimers 13021 1Studies Presented at International Conference on Alzheimers Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimers 13021 2Studies Presented at International Conference on Alzheimers Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimers 13021 3Studies Presented at International Conference on Alzheimers Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimers 13021 4Studies Presented at International Conference on Alzheimers Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimers 13021 5Studies Presented at International Conference on Alzheimers Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimers 13021 6Studies Presented at International Conference on Alzheimers Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimers 13021 7
...ARBOR, N.Y. (Mon., Jan. 5, 2009) - This month,s i...otocols.org/TOCs/toc1_09.dtl ) features two articl... of molecular processes involved in DNA repair and...omologous recombination is an important mechanism ...occurs, a Displacement Loop, or "D-loop," is forme...
...f., January 5, 2009-- Scientists at Burnham Instit... the structure of the interactions between protein...ing complex (DISC), which is responsible for trigg...search, performed by Stefan Riedl, Ph.D., and coll... Nature , highlights how protein-protein interact...
... January 5, 2009. A recent study shows that shad...California can reduce a homeowner,s summertime ele...ucted last year on 460 single-family homes in Sacr...ity billing data to show that trees can reduce ene...s cool a house. No one is going to get a Nobel Pri...
Other Biology News:Methods for studying DNA repair and protein modification are featured in CSH Protocols 2Burnham researchers discover 'on switch' for cell death signaling mechanism 2California study shows shade trees reduce summertime electricity use 2
OmniSlide thermal Cycler from Thermo Scientific
...ytopathic effect inhibition assays, also known as ...issue culture supernatents; serum from PK studies ...nit is defined as the quantity of interferon requi... of viral infection by 50%. All standards used i...
T4 DNA Polymerase from New England Biolabs
[14C(U)]-L-Amino Acid Mixture, 250Ci (9.25MBq) from PerkinElmer
Biology Products: